Skip to main content

Table 3 Predicting models of remission at time point 2, extended remission and durable remission by multivariable logistic regression analyses (N = 104 patients)

From: Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study

Clinical features present at T1

Model 1: remissiona at T2 (N = 48)

Model 2: extended remissiona (N = 31)

Model 3: durable remissiona (N = 13)

OR

95% CI

P value

OR

95% CI

P value

OR

95% CI

P value

Increased CKb

-

-

-

3.18

1.17–8.67

.024*

-

-

-

Facial erythemab

-

-

-

-

-

-

0.11

0.01–0.81

.030*

Digital ulcersb

-

-

-

0.25

0.08–0.77

.015*

-

-

-

Trombocytopheniab, c

0.05

0.01–-0.44

.006**

-

-

-

-

-

-

FVC % pred (pr 10%)

1.37

1.04–1.79

.026*

1.56

1.13–2.16

.007**

1.71

1.04–2.80

.033*

NSAID medication

-

-

-

-

-

-

0.05

0.00–0.73

.028*

Negative anti-RNP

-

-

-

-

-

-

15.0

1.97–113.59

.009**

  1. Area under receiver operating curve (ROC) was 73% for Model 1, 76% for Model 2 and 83% for Model 3
  2. T1 time point 1, T2 time point 2, CK creatine kinase, FVC % pred percentage of predicted forced vital capacity, NSAIDs nonsteroidal anti-inflammatory drugs, anti-RNP anti-ribonucleoprotein, ROC receiver operating characteristic
  3. * P <.05; ** P <.01
  4. aIncludes patients in remission both on and off therapy; medications allowed were hydroxychloroquine, NSAIDs, corticosteroids at ≤ 5 mg daily, calcium channel blockers, methotrexate, mycophenolate and azathioprine
  5. bEver present at T1
  6. cThrombocytes <100 × 109 platelets/L